Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the utility of serial cardiac magnetic resonance (CMR) imaging for guidance of therapy management in patients treated with anakinra due to recurrent pericarditis (RP), compared with c-reactive protein (CRP) assay alone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anakinra Versus Placebo for the Treatment of Acute MyocarditIS

NCT03018834

Acute Myocarditis

COMPLETED PHASE2/PHASE3

AnakInRa for Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP)

NCT02219828

Idiopathic Recurrent Pericarditis

COMPLETED PHASE4

Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity

NCT06331806

Cardiomyopathy Due to Drug

RECRUITING NA

Anakinra to Prevent Adverse Post-infarction Remodeling (2)

NCT01175018

Acute Myocardial Infarction Heart Failure

COMPLETED PHASE2

Treatment of Acute Pericarditis With Anakinra

NCT03224585

Acute Pericarditis

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recurrent pericarditis (RP) is a specific pathology of the pericardium included within the pericardial syndromes by the guidelines of the European Society of Cardiology (ESC). The latter defines RP as pericarditis occurring after a symptom-free interval of 4-6 weeks from a documented first episode of acute pericarditis; the recurrences rate may range from 15 to 30%, with a significant increment of 50% in patients treated with corticosteroids or not treated with colchicine. The diagnosis of recurrences follows the same criteria utilized for acute pericarditis, and a viral etiology can often be demonstrated.

The pathogenesis of RP is still debated, but they are self-sustained by an autoinflammatory/ autoimmune amplified response following an exogenous or endogenous trigger. In this context, the cytokine interleukin 1 (IL-1) has been implicated as a key mediator of RP. Anakinra, an IL-1 antagonist, is of particular interest because it limits the self-sustained pathway of RP and may reduce the recurrences. The current 2015 ESC guidelines for the diagnosis and management of pericardial diseases recommend anakinra in cases of proven infection-negative, corticosteroid-dependent RP not responsive to colchicine, but it remains debated the duration of the therapy and when to start its tapering. In this context, cardiac magnetic resonance (CMR) imaging has recently emerged as an interesting imaging biomarker capable of detecting pericardial inflammation, proving pericardial edema and late gadolinium enhancement (LGE), and distinguishing three defined pericardial inflammation phases: acute (edema and LGE), subacute (only LGE) and burned-out (no edema nor LGE).

To overcome the 2015 ESC guidelines limitations, the investigators sought to determine the utility of serial CMR imaging for guidance of therapy management in patients treated with anakinra due to RP, compared with the c-reactive protein (CRP) assay alone, as currently recommended.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Pericarditis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1:1 randomization

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CMR-guided therapy management,

The scheme of Anakinra treatment was three months at full dosage, the next three months of therapy at full dosage every other day, and the last three months at halved dosage every other day until the end of treatment. Cardiac magnetic resonance \[no pericardial edema and/or late gadolinium enchantment (LGE)\] guided each anakinra dose reduction. If the tests were positive for ongoing pericardial inflammation \[pericardial edema present or LGE present\], the reduction was postponed, and one more month of therapy was administered before the reduction.

Group Type ACTIVE_COMPARATOR

Anakinra

Intervention Type DRUG

Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences

CRP-guided therapy management,

The scheme of Anakinra treatment was three months at full dosage, the next three months of therapy at full dosage every other day, and the last three months at halved dosage every other day until the end of treatment. Laboratory tests \[C-reactive protein (CRP) \<0.6 mg/dL\] guided each anakinra dose reduction. If the tests were positive for ongoing systemic inflammation (CRP \> 0.6 mg/dL), the reduction was postponed, and one more month of therapy was administered before the reduction.

Group Type ACTIVE_COMPARATOR

Anakinra

Intervention Type DRUG

Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anakinra

Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients treated with anakinra 100 mg/die if ≥ 18 years old, and
* Pediatric patients treated with anakinra 2 mg/kg/die if \< 18 years old
* Pediatric and adult patients treated with anakinra due to corticosteroid-dependent or not responsive to colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) recurrent pericarditis